Slide 1: SomnoMed Investor Presentation Financial Year 2014-15
For personal use only SomnoMed Investor Presentation Financial Year 2014-15 Copyright ® and registered trademark notice ASX Investor Presentation | Page 0
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Continuous growth in volume and revenues
Continuous growth in volume and revenues For personal use only Total unit sales growth 51,355 Revenue growth Number of units $A ’000 34,438 43,438 30,274 35,841 30,878 25,119 18,489 19,543 15,246 12,336 10,714 FY10 FY11 FY12 FY13 FY14 FY15 FY10 FY11 FY12 FY13 FY14* FY15** Volume growth +18.2% year o
Slide 4: Broadening product line, geographic coverage and medical initiatives led to accelerated growth
Broadening product line, geographic coverage and medical initiatives led to an accelerated growth in last two years For personal use only USA Direct Europe APAC Quarterly unit sales Quarterly unit sales Quarterly unit sales 7,000 7,000 7,000 6,000 6,000 6,000 5,000 5,000 5,000 4,000 4,000 4,000 3,00
Slide 5: Geographic split stabilizes as all regions grow
Group Overview Geographic split stabilizes as all regions grow For personal use only Total SomnoDent® devices sold 100% 90% 16% 25% 27% 31% 36% 36% APAC 35,841 80% Europe 16% 30,887 70% USA 12% 12% 60% 25,119 11% 11% 10% 50% 19,543 40% 68% 63% 61% 58% 53% 54% 30% 20% 10% 0% 2009/10 2010/11 2011/12 2
Slide 6: Significant expansion in the number of S&M staff in all regions
Group Overview Two years of significant expansion in the number of S&M staff in For personal use only all regions, stabilising in 2015/16 60 51 50 48 40 38.5 Number of employees 30 20 17 10 0 FY13 FY14 FY15 FY16e Investor Presentation | Slide 5
Slide 7: Main Achievements 2014/15
Group Overview Main Achievements 2014/15 For personal use only o Expansion into new markets – Finland, UK, Ireland, Spain, Portugal, Italy o FDA approval and launch of three new products in US (SomnoDent Fusion®, SomnoDent Herbst Advance® and SomnoDent Air®) o FDA approval for DentiTrac™ Compliance
Slide 8: Summary Profit & Loss
Finance Summary Profit & Loss For personal use only 09/10 10/11 11/12 12/13 13/14 14/15* Financial Summary – AUD $000’s Total Group Revenue** 10,714 12,335 15,246 18,489 30,274 34,438 MAS revenue 9,741 12,063 14,765 17,885 25,144 28,899 Managed Care revenue - - - 200 4,704 5,161 Other revenue 973 27
Slide 9: Regional expansion of S&M as a % of MAS revenues
Finance Group Overview Regional expansion of S&M as a % of MAS revenues, now expected to reduce For personal use only from 2015/16 40.0% 35.4% 35.0% 33.4% 33.0% 32.9% 32.4% 32.4% 31.0% 31.5% 30.6% 30.4% 30.0% 28.0% 26.9% 25.3% 25.0% 24.0% 22.0% 22.4% 20.0% 15.0% 10.0% 5.0% 0.0% USA EUROPE APAC TOTAL
Slide 10: Finance Outlook
Finance Finance Outlook For personal use only 2015/16: Improving profitability and secure cash position o MAS gross margin to improve to 69% (+1%) o Expense structure - it is envisaged that over the coming year and in future, the share of regional S&M, as well as administration costs and corporate o
Slide 11: Continuing strong growth in all regions expected in 2015/16
Outlook & Guidance For personal use only Continuing strong growth in all regions expected in 2015/16 o USA - to continue accelerated growth as a result of success of new products and medical initiatives increasing referrals o USA - compliance control roll out into medical practices o EU - new market
Slide 12: Continued and accelerated growth for 15/16 and beyond
Outlook & Guidance For personal use only Continued and accelerated growth for 2015/16 and beyond Guidance 2015/16 o MAS volume → 62,000 MAS units (+20%) o Total group revenues → A$42m (+22%) o MAS gross margin → 69% (+1%) o Group EBITDA → A$3m (+345%) Investor Presentation | Slide 11
Slide 13: Contact details
For personal use only Contact details EXECUTIVE CHAIRMAN & CEO Dr. Peter Neustadt CHIEF FINANCIAL OFFICER Mr. Neil Verdal-Austin Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (2) 9467 0400 Website www.somnomed.com.au Investor Presentation | Slide 12